The DanGer Shock study compared the use of Impella CP mechanical cardiac support with standard care in patients with STEMI complicated by cardiogenic shock. The primary endpoint showed a 26% relative reduction in mortality from any cause. At long-term follow-up of up to 10 years, the absolute reduction in mortality was 16.3%, an increase from the initial 12.7% at six months[2][1]. The median time to death was 577 days in the Impella group versus 61 days in the control group[1]. Impella patients gained an average of 600 more days of life after 10 years[1][2]. The difference in mortality was maintained at 6 years and the benefit signal became more robust[1]. The study included 360 patients from 14 centres in Denmark, Germany and the UK between 2013-2023[2]. Long-term data were presented at ESC 2025 and published in the New England Journal of Medicine[2][3].